We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade

This study has been withdrawn prior to enrollment.
(Funding expired; no subjects enrolled as this was a retrospective chart review)
Sponsor:
ClinicalTrials.gov Identifier:
NCT00233467
First Posted: October 5, 2005
Last Update Posted: September 14, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Lori Davis, MD, Tuscaloosa Research & Education Advancement Corporation
October 3, 2005
October 5, 2005
September 14, 2017
September 1, 2005
September 30, 2005   (Final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00233467 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade
Characterization of the Use of Antipsychotics in Posttraumatic Stress Disorder During the Past Decade
The main purpose is to show the percentage of patients taking antipsychotics with PTSD by looking at approximately ten year's worth of data from 1994 through 2004. We will also determine the type and dose of antipsychotics the patients received, and to determine how many of those patients had psychotic versus nonpsychotic symptoms. We will be obtaining this data from the VISN 7 Corporate Data Warehouse. We hypothesize that there has been an overall increase in antipsychotic use in patient's with PTSD over the last 10 years.

This study is a retrospective chart review of patients, at the Tuscaloosa VA Medical Center, who were, treated with antipsychotics as monotherapy or adjunctive therapy.

The data will be retrieved from a computerized list of patients treated at the TVAMC for PTSD from 1994-2004 Charts will be reviewed by looking at approximately ten year's worth of data. Charts will then be examined to determine what type of antipsychotics patients were prescribed, the dose and duration of the antipsychotics, and the presence or absence of documented psychotic symptoms.

Observational
Observational Model: Other
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample
Chart review of Veterans on antipsychotics
  • PTSD
  • Posttraumatic Stress Disorder
Not Provided
Not Provided
Kozarić-Kovacić D, Pivac N, Mück-Seler D, Rothbaum BO. Risperidone in psychotic combat-related posttraumatic stress disorder: an open trial. J Clin Psychiatry. 2005 Jul;66(7):922-7.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
September 30, 2005
September 30, 2005   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Have a diagnosis of PTSD (309.81)
  2. Male or female patients at least 19 years of age

Exclusion Criteria:

• None

Sexes Eligible for Study: All
19 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00233467
TREAC Retro PTSD
Not Provided
Not Provided
Not Provided
Lori Davis, MD, Tuscaloosa Research & Education Advancement Corporation
Tuscaloosa Research & Education Advancement Corporation
Not Provided
Principal Investigator: Rebecca Seamans, PharmD Tuscaloosa VA Medical Center
Tuscaloosa Research & Education Advancement Corporation
September 2017